Form 4: Gossamer Bio CMO Stock Options Repriced to $0.45

Gossamer Bio's Chief Medical Officer, Richard Aranda, had over 1.9 million stock options repriced to an exercise price of $0.45 per share, effective March 19, 2026.

Summary

• Richard Aranda, Chief Medical Officer of Gossamer Bio, Inc. (GOSS), reported a one-time repricing of his outstanding stock options.
• Effective March 19, 2026, the exercise price for 1,948,118 stock options was reduced to $0.45 per share.
• These options were originally granted under the company's 2019 Incentive Award Plan with previous exercise prices ranging from $0.838 to $2.88.
• All other terms and conditions of the repriced options, including vesting schedules and expiration dates, remain unchanged.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal for existing shareholders, as option repricing typically occurs after significant stock price declines and can be perceived as dilutive. While it aims to re-incentivize management, it highlights past underperformance.

Positives

• The repricing significantly reduces the exercise price for the Chief Medical Officer's stock options, potentially increasing their in-the-money value and re-establishing incentive.
• The repricing applies to a substantial number of options (1,948,118), indicating a broad impact on the executive's equity incentives and potential for renewed motivation.

Negatives

• Stock option repricing typically occurs when a company's stock price has fallen significantly below previous grant prices, suggesting poor past stock performance.
• Repricing can be viewed negatively by existing shareholders as it effectively gives executives a 'do-over' on underwater options, potentially diluting existing shareholder value without requiring them to earn back the original value.
• The new exercise price of $0.45 is substantially lower than the original prices, implying a significant decline in the company's stock value.

Risks

• Potential for shareholder dissatisfaction due to perceived dilution or unfair executive compensation practices.
• Risk of negative market reaction if investors interpret the repricing as a signal of management's lack of confidence in the stock's recovery to previous, higher levels.
• The underlying reason for the options being 'underwater' (i.e., stock price below exercise price) could indicate ongoing operational or financial challenges for Gossamer Bio.

Future Outlook

The repricing aims to re-incentivize the Chief Medical Officer by making a significant portion of his equity awards in-the-money, potentially aligning his future performance with shareholder value creation from the new, lower base.

Industry Context

StockSavvy.ai notes that option repricing is a common, albeit often controversial, practice in the biotechnology and pharmaceutical sectors, especially for companies whose stock prices have experienced significant volatility or decline. It is typically done to restore the incentive value of underwater options for key executives, aiming to retain talent and motivate future performance in a highly competitive industry.

Comparison to Industry Standards

• StockSavvy.ai observes that while option repricing is not uncommon, the extent of the reduction from original exercise prices (e.g., from $2.88 to $0.45) is substantial.
• This magnitude of repricing is often seen in companies that have experienced significant setbacks or prolonged periods of underperformance, particularly in the volatile biotechnology sector.
• Such actions are typically undertaken to re-align executive incentives when existing equity awards are significantly 'underwater,' a strategy employed across various industries to retain key talent following periods of stock price weakness.

Stakeholder Impact

• Shareholders: Potential negative impact due to perceived dilution and the signal of past stock underperformance.
• Employees (executives): Positive impact for the Chief Medical Officer, as his equity incentives are restored, potentially boosting morale and retention.

Next Steps

• Continued vesting of the repriced stock options according to their original schedules.

Key Dates

Recommendation

The repricing of a significant number of executive stock options to a much lower exercise price suggests substantial past stock underperformance. While it aims to re-incentivize management, it can be viewed negatively by shareholders due to potential dilution and the implication of a reset in valuation expectations. A 'hold' recommendation allows investors to monitor whether this re-incentivization translates into improved operational performance and stock price recovery, rather than reacting solely to a compensation event that reflects past challenges.

Keywords

Gossamer Bio, GOSS, stock options, repricing, executive compensation, Form 4, insider transaction, Chief Medical Officer, equity incentives